RT Journal Article
SR Electronic
T1 Clinical features and management of severe COVID-19: A retrospective study in Wuxi, Jiangsu Province, China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.10.20060335
DO 10.1101/2020.04.10.20060335
A1 Xiufeng Jiang
A1 Jianxin Tao
A1 Hui Wu
A1 Yixin Wang
A1 Wei Zhao
A1 Min Zhou
A1 Jiehui Huang
A1 Qian You
A1 Meng Hua
A1 Feng Zhu
A1 Xiaoqing Zhang
A1 Meifang Qian
A1 Yuanwang Qiu
YR 2020
UL http://medrxiv.org/content/early/2020/04/14/2020.04.10.20060335.abstract
AB Objective We aimed to investigate clinical features and management of 55 COVID-19 patients in Wuxi, especially severe COVID-19.Methods Epidemiological, demographic, clinical, laboratory, imaging, treatment, and outcome data of patients were collected. Follow-up lasted until April 6, 2020.Results All 55 patients included 47 (85.5%) non-severe patients and 8 (14.5%) severe patients. Common comorbidities were hypertension and diabetes. Common symptoms were fever, cough and sputum. Lymphopenia was a common laboratory finding, and ground-glass opacity was a common chest CT feature. All patients received antiviral therapy of α-interferon inhalation and lopinavir-ritonavir tablets. Common complications included acute liver injury and respiratory failure. All patients were discharged. No death was occurred and no medical staff got infected. Patients with severe COVID-19 showed significantly older age, decreased lymphocytes, increased C reactive protein, and higher frequency of bilateral lung infiltration compared to non-severe patients. Significantly more treatments including antibiotic therapy and mechanical ventilation, longer hospitalization stay and higher cost were shown on severe patients.Conclusions Our study suggested that patients with severe COVID-19 may be more likely to have an older age, present with lymphopenia and bilateral lung infiltration, receive multiple treatments and stay longer in hospital.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Wuxi Municipal Health Commission Major Project (Z201811); Wuxi Science and Technology Bureau COVID-19 special project (N2020X009); Wuxi Science and Technology Bureau guiding plan (201812).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request.